Novo Not Discussing Further Pill Discounts, CEO Says
Share
Novo Nordisk A/S Chief Executive Officer Mike Doustdar talks about the company's performance as its popular Wegovy weight-loss pill disappointed investors with sales that failed to live up to the hype. "We are not right now discussing further discounts," Doustdar tells Bloomberg's Francine Lacqua.
More from Australia
Titanium Sands secures $500,000 Sri Lankan funding
WIN Metals expands Butchers Creek gold tenure package
Forte Energy enters South American oil exploration agreement
Pathkey.AI validates Chipforge platform through independent testing
Arovella Therapeutics names acting CEO
Ingenia Communities rejects new Warburg Pincus buyback offer